In order, Abbott Laboratories (NYSE: ABT), Danaher Corp. (NYSE: DHR) and Boston Scientific Corp. (NYSE: BSX) combine for about 20% of IHI’s weight.
What’s Next for the U.S. Economy
There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.
“Abbott has established new guidance for 2019. It expects organic sales growth of 6.5%-7.5%, which excludes the impact of foreign exchange. It also expects adjusted EPS of $3.15-$3.25. Based on the updated guidance, we are maintaining our 2019 adjusted EPS estimate of $3.22. We are setting a 2020 estimate of $3.65,” according to Forbes.
Abbott is IHI’s largest holding at 8.80% of the fund’s weight.
“Boston Scientific struck Maley because of its notably positive action in recent months, with shares up over 25 percent since their late-December lows,” reports CNBC. “Danaher’s recent announcement that it will purchase General Electric’s biopharmaceutical business has lifted its stock, which Maley said was ‘breaking out’ regardless of the news.”
For more information on the U.S. markets, visit our sector ETFs category.
